Member access

4-Traders Homepage  >  Shares  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

NOVARTIS AG (NOVN)

237
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
Latest news on NOVARTIS AG
03/05DJVectura Group to Receive $20 Million in Milestone Payments from Novartis
03/05 AbbVie boosts cancer drug pipeline with $21 billion Pharmacyclics deal
03/04 DIPLOMAT PHARMACY : to Dispense Novartis Myeloma Drug FARYDAK®
03/04DJJohnson &Johnson Near Deal for Drugmaker Pharmacyclics -FT
03/04 NOVARTIS : receives FDA approval of Farydak®, the first HDAC inhibitor for patie..
03/04 NOVARTIS : First independent U.S. psoriasis registry will track drug safety and ..
03/04 NOVARTIS : Patent Issued for Intraocular Lens Transfer Case
03/04 NOVARTIS : "Treatment of Fibrosis" in Patent Application Approval Process
03/04 NOVARTIS : Study Findings on Fragile X Syndrome Are Outlined in Reports from Nov..
03/04 NOVARTIS : Free medical camp
03/03 NOVARTIS : $1.97 Million Federal Contract Awarded to Sandoz
03/03 GLAXOSMITHKLINE : In Brief : Deals finalised by GSK and Novartis
03/03 NOVARTIS : GSK gives £4bn windfall after Novartis deal
03/03 Clinigen Group Announces half year revenues up 17% to £72.6m, underlying EBIT..
03/03 NOVARTIS AG : ex-dividend day for annual dividend
03/02 NOVARTIS : EMA committee issues positive opinion for Novartis' lung cancer drug ..
03/02 NOVARTIS : GSK acquires Novartis vaccine business
03/02 NOVARTIS : GSK completes transaction with Novartis
03/02 GSK and Novartis complete deals to reshape both drugmakers
03/02 NOVARTIS : announces completion of transactions with GSK »
03/02 NOVARTIS : CONTRACT AWARD - 65-- Nadolol Tablets Sandoz, Inc. Effective: 7/1/201..
03/02 NOVARTIS : lung cancer drug Zykadia® recommended for EU approval in patients wit..
03/02 NOVARTIS : Cosentyx™: First IL-17A Antagonist for Moderate-to-Severe Plaqu..
03/02 NOVARTIS : lung cancer drug Zykadia recommended for EU approval in patients with..
03/02 NOVARTIS : shareholders approve all resolutions proposed by Novartis Board of Di..
03/02DJNovartis, GlaxoSmithKline Complete Series of Deals - Update
03/02 GlaxoSmithKline To Set Out Guidance When It Reports On May 6
03/02DJNovartis, GlaxoSmithKline Complete Deals
03/02DJNovartis, GlaxoSmithKline Complete Series of Deals
03/02 NOVARTIS : receives FDA approval of Farydak®, the first HDAC inhibitor for patie..
03/02 NOVARTIS' : heart failure medicine LCZ696 granted FDA priority review »
03/02 NOVARTIS : Positive phase II data highlights benefits of Alcon's RTH258 for pati..
03/02 NOVARTIS : shareholders approve all resolutions proposed by Novartis Board of Di..
03/02 NOVARTIS : announces completion of transactions with GSK
02/28 OPHTHOTECH : Releases Fourth Quarter and Full Year 2014 Financial Results
02/27 Bs1000-2015 rankings by consolidated total revenues: novartis india limited (..
02/27 NOVARTIS : Positive phase II data highlights benefits of Alcon's RTH258 for pati..
02/27 NOVARTIS : Competition Commission of Pakistan approves acquisition of global vac..
02/27 NOVARTIS : Competition Commission of Pakistan approves acquisition of global vac..
02/27DJNOVARTIS : Japan Ordered to Shut Down for Failure to Report Side Effects
02/27 NOVARTIS : shareholders approve all resolutions proposed by Board of Directors
02/27 NOVARTIS : lung cancer drug Zykadia® recommended for EU approval in patients wit..
02/27 NOVARTIS : Japan unit ordered to suspend business for 15 days
02/26 NOVARTIS : CCP approves acquisition of global vaccine business
02/26 GSK's new chairman Hampton to take charge in May
02/26 NOVARTIS : CCP approves acquisition of global vaccine business by GSK from Novar..
02/26 NOVARTIS : CCP approves acquisition of global vaccines business
02/26 NOVARTIS : PM and his deputy back Harmonie vaccine call
02/26 NOVARTIS : GSK -Update on three-part transaction with Novartis
02/26 NOVARTIS : Secures FDA Approval of Farydak
02/26 OPHTHOTECH : Releases Fourth Quarter and Full Year 2014 Financial Results
02/26 NOVARTIS' : heart failure medicine LCZ696 granted FDA priority review
02/26 NOVARTIS : Mergers acquisitions: CCP conditionally approves GSK's acquisition of..
02/25 NOVARTIS : Patent Issued for Short Interfering Ribonucleic Acid (SiRNA) for Oral..
02/25DJPharmacyclics Mulls Sale of Company -Bloomberg
02/25 GSK set to complete $20 billion Novartis asset swap next week
02/25DJGlaxoSmithKline to Complete Novartis Deal in March
02/25 GSK set to complete 13 billion pounds Novartis asset swap next week
02/25 NOVARTIS : Alcon LenSx Assigned Patent
02/24DJNovartis Says FDA Has Approved Use of Farydak to Treat Multiple Myeloma
02/23 NOVARTIS : FDA approves Novartis drug for bone marrow cancer
02/23DJNOVARTIS : Press Release : FDA Approves Farydak for Treatment of Multiple Myelom..
02/23 NOVARTIS : receives FDA approval of Farydak®, the first HDAC inhibitor for patie..
02/20 NOVARTIS : Vanda Pharmaceuticals Reports Fourth Quarter 2014 and Full Year 2014 ..
02/20 NOVARTIS : NCI -U Penn researchers develop personalized cellular therapy for bra..
02/19 Australian regulator says will not oppose GSK, Novartis deals
02/18 GLAXOSMITHKLINE : Pharmaceuticals announces Q4 Results
02/18 NOVARTIS : Alcon Research Assigned Patent
02/17 Gsk pharma to transfer cancer portfolio to novartis arm
02/17 GLAXOSMITHKLINE PHARMACEUTICALS : Gsk pharma to shift cancer drug portfolio to n..
02/16 NOVARTIS : gets FDA priority review for heart failure medicine LCZ696
02/16 NOVARTIS' : heart failure medicine LCZ696 granted FDA priority review
02/13 NOVARTIS : ' heart failure medicine LCZ696 granted FDA priority review
02/13 NOVARTIS : $425,000 Federal Contract Awarded to Alcon Laboratories
02/12 NOVARTIS : Blueprint Medicines Appoints Anthony Boral, M.D., Ph.D., as Senior Vi..
Prev.1   2  3  4  5  6  7  8  9  10Next
Advertisement
Chart
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF